Haemonetics (NYSE:HAE – Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Haemonetics to post earnings of $0.88 per share for the quarter. Haemonetics has set its FY 2024 guidance at 3.900-4.000 EPS and its FY24 guidance at $3.90-4.00 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.
Haemonetics (NYSE:HAE – Get Free Report) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. During the same period last year, the firm posted $0.85 EPS. The company’s revenue was up 10.1% on a year-over-year basis. On average, analysts expect Haemonetics to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Haemonetics Stock Performance
NYSE HAE opened at $95.35 on Tuesday. The company has a fifty day moving average of $82.81 and a two-hundred day moving average of $82.69. The company has a market capitalization of $4.84 billion, a PE ratio of 38.76, a P/E/G ratio of 2.23 and a beta of 0.34. Haemonetics has a 1 year low of $70.74 and a 1 year high of $96.25. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76.
Wall Street Analyst Weigh In
Get Our Latest Research Report on HAE
About Haemonetics
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.
Recommended Stories
- Five stocks we like better than Haemonetics
- Election Stocks: How Elections Affect the Stock Market
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Value Stocks You Can Buy Before They Become Big
- Insider Trading – What You Need to Know
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.